ANCA vasculitis induction management during the COVID-19 pandemic

Antonio Salas
Johns Hopkins University
Tingting Li
Washington University School of Medicine in St. Louis
et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

Recommended Citation
Salas, Antonio; Li, Tingting; and et al., "ANCA vasculitis induction management during the COVID-19 pandemic." Kidney International Reports. 6, 11. 2903 - 2907. (2021).
https://digitalcommons.wustl.edu/oa_4/1121

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
ANCA Vasculitis Induction Management During the COVID-19 Pandemic

Antonio Salas1, Sam Kant2, Lauren Floyd3, Vojtěch Kratky4, Silke R. Brix5, Maria Prendecki6, Ulf Schönermarck7, Jennifer Scott8, Manish Saha9, Philipp Gauckler10, Tingting Li11, Purva D. Sharma12, Isabelle Ayoub13, Adam D. Morris3, Ajay P. Dhaygude3, Zdenka Hruskova4, Vladimir Tesař4, Stephen P. McAdoo6, Mark A. Little8, Vimal K. Derebail9, Caroline J. Poulton9, Philip Seo14, Andreas Kronbichler10 and Duvuru Geetha15

1Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA; 2Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA; 3Department of Nephrology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; 4Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; 5Renal, Urology and Transplantation Unit, Manchester University Hospitals, Manchester, UK; 6Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK; 7Ludwig-Maximilians-Universität München, Munich, Germany; 8Trinity Health Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Ireland; 9Division of Nephrology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA; 10Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria; 11Washington University School of Medicine, St. Louis, Missouri, USA; 12Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York; 13Division of Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; 14Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA; and 15Division of Nephrology and Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Correspondence: Duvuru Geetha, Division of Nephrology and Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, 4940 Eastern Avenue, 301 Mason Lord Drive, Baltimore, Maryland 21224, USA. E-mail: gduvu@jhmi.edu

Received 2 August 2021; accepted 10 August 2021; published online 19 August 2021


© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

As the severe acute respiratory syndrome coronavirus 2 pandemic evolved and became a global health threat, the safety of immunosuppression in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) became of utmost importance for clinicians and patients. Although timely initiation of immunosuppressive therapy is critical to quell the acute inflammation and prevent AAV-associated mortality and morbidity, concerns for increased susceptibility to Coronavirus Disease 2019 (COVID-19), delayed viral clearance, and decreased humoral response to infection led to speculation about modification in induction therapy practices may be deployed by physicians caring for patients with AAV. This international retrospective cohort study investigated the influence of the COVID-19 pandemic on AAV induction therapy and patient outcomes in different parts of the world by studying differences in treatment regimens in the United States, United Kingdom, and Europe.

RESULTS

Of the 191 patients, mean age was 65 (SD 14). 52% were women with most (89%) being Caucasian. Kidney involvement was present in 155 (81%) patients and mean entry estimated glomerular filtration rate was 34 (SD 31) ml/min per 1.73 m², with 21% requiring dialysis at presentation. Baseline characteristics of patients are outlined in Table 1.

With regard to induction immunosuppression, mean cumulative steroid dose for remission induction was 2962 mg (SD 1841), with the United States having the highest average dose, which was 4153 mg (SD 2427), P < 0.001. Prednisone regimen stratified by time course, center, and region is presented in Table 2. Forty-six patients (26%) in the whole cohort were off corticosteroids at 6 months, whereas 14 (36%) US patients, 16 (21%) UK patients, and 16 (26%) European
patients were no longer given steroid treatment at 6 months ($P = 0.21$).

Eighty-four patients (44%) received rituximab treatment without cyclophosphamide, with the United States having the highest proportion undergoing this treatment regimen (64% of patients; $P = 0.005$). On the other hand, 49 (26%) patients were treated with cyclophosphamide without rituximab for induction treatment and Europe had the highest proportion of patients given cyclophosphamide alone (33%; $P = 0.037$) (Table 2).

The outcomes of remission induction therapy are depicted in Supplementary Table S1. At 6 months, 73 (92%) patients in the rituximab group, 42 (91%) patients in the cyclophosphamide group, and 39 (87%) patients who underwent combined therapy reached remission ($P = 0.564$). Mean estimated glomerular filtration rate at 6 months was 43 (SD 29) ml/min per 1.73 m² in the rituximab group, 33 (SD 24) ml/min per 1.73 m² in the cyclophosphamide group, and 47 (SD 36) ml/min per 1.73 m² for those who received combination therapy ($P = 0.0659$). In addition, the rituximab, cyclophosphamide, and combination groups all had a median increase in glomerular filtration rate of 6 ml/min per 1.73 m² over 6 months ($P = 0.68$) (Supplementary Table S1; Supplementary Methods).

Nineteen patients (61%) of the surviving 31 (2 patients died) had kidney recovery at the end of the study after presenting with dialysis-dependent kidney failure. Nineteen patients reached end-stage kidney disease at the end of follow-up with similar incidence across the different induction regimens.
Sixteen patients were diagnosed with COVID-19 during the induction period, with similar cyclophosphamide and rituximab exposure, and half of these patients received combined therapy (Supplementary Table S2; Supplementary Methods). The median interval from AAV diagnosis or relapse to COVID-19 infection was 33 (interquartile range 4–168) days. Patients who had COVID-19 infection had similar treatment regimens compared with patients who tested negative for severe acute respiratory syndrome coronavirus 2 (Supplementary Table S2). Of the patients with COVID-19, 4 patients died of COVID-19, of whom 3 (75%) had received combined rituximab and cyclophosphamide therapy, and the other patient received cyclophosphamide alone. The median cumulative steroid induction dose for patients who died and had COVID-19 was 2423 (interquartile range 1210–5370) mg and the mean cumulative methylprednisolone dose for this group was 937.5 mg (SD 125). Of the patients with COVID-19, 7 were hospitalized for infectious causes (1 of whom had cellulitis and another had bacteremia). Outcomes of patients diagnosed with COVID-19 are summarized in Supplementary Table S3 (Supplementary Methods).

Differences in outcomes among the United States, United Kingdom, and European cohorts, between with new and relapsing AAV, and in treatment of patients with relapsing and new disease are summarized in Supplementary Tables S4, S5, and S6, respectively (Supplementary Methods).

**DISCUSSION**

This international multicentered retrospective cohort study demonstrates that there was no deviation in the standard of care induction therapy of AAV during the pandemic, and, more importantly, a less aggressive regimen was not used, highlighting the importance of optimal vasculitis management. Both rituximab and...
cyclophosphamide induction regimens had similar infectious risk, remission rate, and kidney function outcomes in our study. This complements previous studies that suggest that adverse events, remission induction, and kidney function improvement are similar in both regimens. Our data also show that there were no differences in susceptibility to COVID-19 in our AAV cohort. Therefore, a change in induction regimen may not be warranted, and robust control of disease activity should continue to be prioritized in the current pandemic. This study additionally demonstrates significant center-based differences in induction treatment regimens and predominant use of rheumatoid arthritis dosing regimen for rituximab.

Interestingly, the rituximab group had the lowest mean cumulative steroids dose for induction and had the lowest proportion of patients who received pulse methylprednisolone therapy, whereas the cyclophosphamide group had the highest proportion of patients given pulse methylprednisolone and had the highest mean cumulative steroid dose for induction. Notably, a reduced steroid exposure in rituximab-treated patients compared with cyclophosphamide-treated patients was also reported in the RAVE trial, despite using the same glucocorticoid regimen in both treatment arms. This might reflect a higher confidence in the long-acting effect of B-cell depletion by the prescribing physician or a higher rate of true remission.

In our patients, there was a high proportion of patients still treated with glucocorticoids at the 6-month follow-up, which is consistent with multiple centers having corticosteroid taper regimens extending past this period. In addition, this cohort was enriched with rituximab-treated patients receiving 2 doses of 1000 mg given 2 weeks apart compared with the Food and Drug Administration–approved regimen of 375 mg/m² once weekly for 4 weeks. This trend in dosing regimen likely evolved with the need to minimize exposure to severe acute respiratory syndrome coronavirus 2 virus in health care settings, although it is possible that some centers use this regimen as their standard of rituximab treatment for AAV induction. Use of PLEX therapy was low in our study population, which may be influenced by changes to practice patterns after the PEXIVAS study, which showed that PLEX therapy did not improve mortality or end-stage kidney disease outcomes in patients with severe AAV.

There were multiple differences in AAV induction therapy practices among the United States, United Kingdom, and Europe. Despite the United Kingdom having the highest proportion of patients presenting in AAV relapse, the United States had the highest proportion of patients given rituximab treatment, which is consistent with recent AAV treatment trends in the United States. On the other hand, patients in the United Kingdom and Europe used cyclophosphamide therapy more than those in the United States. The United States had the highest corticosteroid use among all locations studied. A more widespread usage of the initial high-dose intravenous steroid pulse in the US cohort resulted in the highest cumulative steroid dose for induction among all locations studied. Despite the difference in steroid dosing, no differences were observed in the daily steroid doses of patients at 16-week and 6-month intervals or in the proportion of patients off glucocorticoids at 6 months.

A high proportion of patients with COVID-19 in this cohort were hospitalized for infection and died. This study was conducted before the RECOVERY trial, which showed favorable data about use of oral dexamethasone and tocilizumab for COVID-19 management, and may help explain why the patients with COVID-19 in our cohort had poor outcomes. Immunosuppressed patients with these updated therapies may have improved outcomes compared with our study.

Our study is subject to limitations inherent in a retrospective study. We were unable to assess long-term kidney outcome and relapse because of the short follow-up period. Our analysis on COVID-19 susceptibility was limited by the lack of universal testing for severe acute respiratory syndrome coronavirus 2 infection. This is the first study evaluating AAV induction therapy patterns and outcomes during the COVID-19 pandemic, highlighting the importance of optimal management of active vasculitis in times of the pandemic. Preliminary experience from case cohort studies highlights that immunosuppression may not confer the highest risk of COVID-19 vulnerability. Therefore, it is recommended that standard immunotherapy be continued in AAV to minimize vasculitis-related morbidity and mortality.

**DISCLOSURES**

US receives grants and nonfinancial support from Alexion Pharma, and grants and nonfinancial support from Ablynx and Chemocentryx. BCT; and personal fees from Vifor Pharma and Alexion. VKD has been a consultant to Novartis, on the advisory board for Bayer and Travere, and received royalties and honoraria from UpToDate. AK received personal fees from Novartis, Terumo BCT, Miltenyi Biotech, Vifor Pharma, and Alexion. DG has been a consultant to ChemoCentryx and Aurinia. All the other authors declared no competing interests.

**ACKNOWLEDGMENTS**

DG is supported by the Gorski Fund.
SUPPLEMENTARY MATERIAL
Supplementary File (PDF)

Supplementary Methods

Table S1. Different clinical outcomes by different treatment regimens.

Table S2. Treatment differences among patients who tested positive and negative for COVID-19.

Table S3. Outcomes of patients diagnosed with COVID-19.

Table S4. Patient outcomes of the US, UK, and European cohorts.

Table S5. Outcomes of patients with new and relapsing AAV.

Table S6. Treatment variables of patients with new and relapsing AAV.

REFERENCES


